Data were retrospectively collected from the medical records, and the following parameters were reviewed at relapse or followup: age, gender, complete blood cell count (CBC), WBC differential count, LUC, blast suspect, DN II, DN I, French-American-British (FAB) subtype, overall survival (OS) time, date of bone marrow aspiration, and date of allogeneic HSCT.
ADVIA 2120i (Siemens Healthcare Diagnostics) automatic blood analyzer was used for the calculation of CBC, LUC, blast suspect, DN II, and DN I. This analyzer is based on a ow cytometry method and employs two independent channels to analyze WBCs. One of these is a peroxidase channel containing 4-chloro-1-naphthol as the substrate for myeloperoxidase (MPO) from granulocytes that forms a black precipitate within cells. As the stained WBCs pass through the ow cell, a tungsten-halogen light source records and measures light scatter (size) and absorbance (staining intensity).
The second channel is a basophil/lobularity channel that uses a 670 nm laser diode for the measurement of forward scatter (size) and side scatter (nuclear complexity). DN I was calculated as per the following formula: DN I (%) = (neutrophil subfraction and eosinophil subfraction assayed in peroxidase method)−(polymorphonuclear subfraction measured in basophil/lobularity method). Mann-Whitney U test or t-test was employed for comparison of continuous variables between the relapse and control groups. Logistic regression analysis was carried out to evaluate the relative prediction effect of LUC, blast suspect, DN II, and DN I for the detection of leukemia relapse in peripheral blood samples. Receiver operating characteristic (ROC) analysis was performed to evaluate the diagnostic performance of each parameter, while KaplanMeier OS analysis was carried out to estimate the distribution of OS. OS was measured from the date of diagnosis to the date of death or last follow-up. Statistical signi cance was set at P <0.05.
RESULTS
The clinical characteristics of the patients from leukemia relapse and control groups are summarized in Table 1 . The data from a total of 112 cases including acute leukemia relapse, non-relapsed acute leukemia, and normal bone marrow were collected.
Of the patients from leukemia relapse group, 40 and 14 were diagnosed with AML and ALL, respectively. In the control group, 14 and 12 patients were diagnosed with AML and ALL, respectively.
The most common FAB subtype among patients with AML relapse was AML M2 (32.2%).
The mean age was 53.1±14.0 and 49.7±15.6 years for the subjects from relapse and control groups, respectively. The relapse group comprised 25 women and 31 men, and the control group included 23 women and 33 men. The CBC results for the patients with relapse revealed the increase in the prevalence of anemia, leukocytosis, and thrombocytopenia as compared with the subjects from the control group (Table 1) . We observed signi cant (Fig. 1) .
In ROC curve analysis, all parameters except DN I showed good diagnostic performance. Blast suspect showed 82.1% sensitivity and 96.4% speci city at a cutoff value of 5.5%, while 83.9% sensitivity and 89.3% speci city was reported for LUC at a cutoff value of 3.9%. DN II showed 83.9% sensitivity and 85.7% speci city at a cutoff value of 6.8%, and the sensitivity and speci city of DN I at a cutoff value of 2.2% were 57.1% and 76.8%, respectively. The value of AUC was 0.927 for blast suspect (95% CI: 0.875-0.978, P <0.001), However, no statistical signi cance was observed for the survival analysis with DN I (Fig. 2) .
To identify the values of blast suspect, LUC, DN II, and DN Iessential for the prediction of leukemia relapse, we determined the 
Data are presented as mean±standard deviation or median [IQR] . Abbreviations: IQR, interquartile range; F, female; M, male; BM, bone marrow; PB, peripheral blood; DN I, delta neutrophil index I; DN II, delta neutrophil index ll; LUC, large unstained cell; WBC, white blood cell; PLT, platelet; N, normal; T, T lymphoblastic leukemia; MPAL, mixed phenotype acute leukemia; Hb, hemoglobin. www.labmedonline.org 129 odds ratio (OR) by logistic regression analysis ( (Table 4) .
DISCUSSION
Signi cant improvements have been reported in the treatment of acute leukemia over the last decade, as HSCT can provide cure and long-term survival in 35-40% of patients with adult leukemia [1] . However, leukemia relapse often leads to poor prognosis, and about 20-70% of patients die regardless of pre-transplant disease status, cytogenetic subtype, patient and donor age, and chemotherapy regimen [2, 3] . Although the detection of minimal residual disease with ow cytometry is a reliable method to predict leuke- lignancies is desirable [7, 8] . Since the introduction of automated blood cell analyzers in clinical laboratories, the technology has evolved to incorporate more re ned laser-, optical-, and uorescence-based detection systems [8] . and blasts ≥28.5% [10] .
The role of LUC in the diagnosis and monitoring of acute leukemia has been interrogated in several studies [12] [13] [14] . Gibbs et al.
suggested that LUC in ALL and AML may be differentiated with NRBC channel in ADVIA 2120i (Siemens Healthcare Diagnostics) [15] .
LUC has been studied as a prognostic marker for B-cell CLL and may serve as a diagnostic and monitoring marker for viral infectious diseases [16, 17] .
Jang et al. [6] evaluated the diagnostic role of LUC and DN I in the discrimination between APL and other leukemias in bone marrow samples. These authors showed that LUC serves as a better marker than DN I with higher AUC values in ROC curve analy- 
